STAT+: On ASCO Day 4, J&J bets on Rybrevant and airs ‘innovation ecosystem’ concerns

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here.

ASCO ends tomorrow, but alas, dear readers, this newsletter’s run of show is over. At least until next year.

Before you digest our parting words, a couple of housekeeping notes: